Voxelotor (GBT440), a first‐in‐class hemoglobin oxygen‐affinity modulator, has promising and reassuring preclinical and clinical data

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|3|326-329

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.3, 2018-03, pp. : 326-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 175, Iss. 1, 2016-10 ,pp. : 141-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sickle hemoglobin oxygen affinity‐shifting strategies have unequal cerebrovascular risks

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 321-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

By  

Cardiology, Vol. 108, Iss. 1, 2006-09 ,pp. : 40-47

Karger

Access to resources Recommend Favorite

Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 299-301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 12, 2015-12 ,pp. : 1427-1437

John Wiley & Sons Inc

Access to resources Recommend Favorite